Types of Cancer We Treat

Bladder Cancer

As leaders in the development of the most sophisticated treatments for people with bladder cancer, we have one of the largest bladder cancer clinical trials programs in the United States. A team of urologic surgeons, medical oncologists, imaging specialists, and urologic pathologists collaborates to diagnose and treat people with bladder cancer.

Our research studies give you access to the newest approaches to care, including the latest diagnostic imaging techniques, such as PET/MRI scans, and advanced treatments, including immunotherapy, robotic-assisted surgery, and blue light cystoscopy to detect and remove early stage bladder cancer.

Meet Our Doctors
Dr. Arjun Balar
Our Approach to Bladder Cancer Treatment Our Approach to Bladder Cancer Treatment
Diagnosis
Bladder Cancer Diagnosis
Transurethral Resection
Bladder Cancer Transurethral Resection
Intravesical Therapy
Bladder Cancer Intravesical Therapy
Surgery
Bladder Cancer Surgery
Chemotherapy & Immunotherapy
Bladder Cancer Chemotherapy & Immunotherapy
Radiation Therapy
Bladder Cancer Radiation Therapy

Related News

Urologic Cancer Expert Brings Latest Science to Brooklyn
Read Story
NYU Langone Bladder Cancer Surgeon Advances Treatments
Read Story
Gary Steinberg, MD, to Lead Urology Bladder Cancer Program
Read Story
After Testing, Novel Bladder Cancer Treatments Win Approval
Read Story
Research Yields New Treatments for Advanced Bladder Cancer
Read Story
Immunotherapy Provides New Options for Advanced Cancers
Read Story
NYU Langone Research Leads to Bladder Cancer Drug Approval
Read Story
Atezolizumab Receives FDA Approval to Treat Bladder Cancer
Read Story
Study: New Treatment Shrinks Bladder Cancer Tumors
Read Story
New Drug Atezolizumab Fights Advanced Bladder Cancer
Read Story
Simultaneous PET/MRI Improves Accuracy for Bladder Cancer
Read Story

Clinical Trials and Research Studies

Phase 2

A Phase 2 randomized non-comparative open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible locally advanced or metastatic urothelial cancer patients with low PD-L1 expression (18-214-10 / CA045-012)

Learn More

Phase 1

A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas

Learn More

Phase 2

A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Learn More

Phase 2

Afatinib in advanced refractory urothelial cancer

Learn More
View All Related Clinical Trials (17)